Home›Trial›NCT04303780
🔬NCT04303780Phase 3ACTIVE NOT RECRUITING

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Study Summary

A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation

Conditions
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Interventions / Drugs
AMG 510Docetaxel
View on ClinicalTrials.gov ↗
Sponsor
AMGN
Amgen Inc
Biologics
F33/100
Study Details
Enrollment345 participants
Primary Completion—
Lead SponsorAmgen
Data Retrieved2026-04-13 18:29:34.157130+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.